Clinical Trial Update: A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer (MK-2870-027) [Phase 1, Phase 2]

View source ↗

Summary

Merck is conducting a Phase 1/2 clinical trial of Sacituzumab Tirumotecan (MK-2870) for non-muscle invasive bladder cancer, and the study is currently recruitin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-muscle Invasive Bladder Cancer

Drugs mentioned

• Sacituzumab Tirumotecan (MK-2870) (sacituzumab tirumotecan)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Non-Muscle Invasive Bladder Cancer | Phase 1, Phase 2 | Status: RECRUITING